---
title: Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage
nct_id: NCT02396303
overall_status: UNKNOWN
phase: EARLY_PHASE1
sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
study_type: INTERVENTIONAL
primary_condition: Postpartum Haemorrhage
countries: Bangladesh
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02396303.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02396303"
ct_last_update_post_date: 2015-03-24
last_seen_at: "2026-05-12T06:16:22.514Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage

**NCT ID:** [NCT02396303](https://clinicaltrials.gov/study/NCT02396303)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** EARLY_PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Conditions:** Postpartum Haemorrhage
- **Start Date:** 2015-06
- **Completion Date:** 2015-11
- **CT.gov Last Update:** 2015-03-24

## Brief Summary

Post-partum haemorrhage is one of the life threatening emergencies. It accounts for nearly one-quarter of all maternal death worldwide. Atonic uterus contributes about 80% among the causes. Uterotonic drugs are administered following the delivery of baby both in vaginal and caesarean delivery for prevention of PPH. However postpartum haemorrhage cannot always be prevented. But, the incidence and especially its magnitude can be reduced by assessing the risk factors and following the guidelines. The intelligent anticipation, skilled supervision, prompt detection and effective institution of therapy can prevent a normal case from undergoing disastrous consequences. This study will be carried out at Bangabandhu Sheikh Mujib Medical University (BSMMU) within six months after approval. This is a Randomized Control Trial which will compare efficacy of Carbetocin and Oxytocin for the control of PPH. Structured Questionnaire, Data Sheet, hospital indoor documents i.e. Patient chart, operation notes, surgeons visual estimation of blood loss etc will be used as study tool. Ethical clearance will be obtained from Institutional Review Board of BSMMU. Written informed consent will be obtained from the patient or from her legal guardian. Patient confidentiality will be strictly maintained. No name, address or contact details of the patient will be divulged.

## Eligibility

- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Patient with risk factors for primary post-partum haemorrhage such as: multiple pregnancy, one or more previous caesarean section, presence of uterine fibroids, previous myomectomy, presence of placenta previa, past history of PPH, fetal macrosomia and fetal malformations associated with polyhydramnios

Exclusion Criteria:

* Presence of hypertension, eclampsia, cardiac, renal or liver diseases, epilepsy, general anaesthesia, as well as women with history of hypersensitivity to Carbetocin according to the Br National Formulary. Patients unwilling to give consent for this study are also excluded
```

## Arms

- **Patient receiving carbetocin** (EXPERIMENTAL) — Experimental group subjects will receive intravenous Carbetocin during third stage of labour.
- **Patient receiving oxytocin** (ACTIVE_COMPARATOR) — Comparator group subjects will receive intramascular Oxytocin during third stage of labour.

## Interventions

- **Carbetocin** (DRUG)

## Primary Outcomes

- **Estimated blood loss after cesarean section** _(time frame: 24 hours of delivery)_

## Locations (1)

- BSMMU, Dhaka, Bangladesh

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.bsmmu|dhaka||bangladesh` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02396303.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02396303*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*